HC Wainwright Has Bearish Forecast for Neurogene Q3 Earnings

Key Points

• HC Wainwright revised its Q3 2025 earnings per share forecast for Neurogene from ($1.08) to ($1.14), while maintaining a "Buy" rating with a target price of $45.00.
• Other analysts, including Robert W. Baird, have downgraded Neurogene's rating and reduced price targets, reflecting cautious sentiment toward the company's future performance.
• Neurogene's current market cap is approximately $301.24 million, with a past 52-week stock range from $6.88 to $74.49.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 EPS estimates for Neurogene in a report issued on Tuesday, August 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($1.14) per share for the quarter, down from their previous forecast of ($1.08). HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene's Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.45) EPS, Q1 2026 earnings at ($1.21) EPS, Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($1.28) EPS and FY2026 earnings at ($4.98) EPS.

Several other equities analysts also recently commented on the stock. Baird R W downgraded shares of Neurogene from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. Robert W. Baird downgraded shares of Neurogene from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $38.00 to $24.00 in a research note on Friday, May 16th. BMO Capital Markets reaffirmed an "outperform" rating and set a $26.00 price objective (up from $22.00) on shares of Neurogene in a research note on Thursday, June 12th. Finally, Craig Hallum initiated coverage on shares of Neurogene in a research note on Tuesday, June 17th. They set a "buy" rating and a $50.00 price objective for the company. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $46.17.

Neurogene Stock Down 2.8%

Shares of NASDAQ:NGNE traded down $0.5750 during midday trading on Thursday, hitting $19.8750. 40,303 shares of the stock traded hands, compared to its average volume of 229,175. The stock has a market capitalization of $283.62 million, a PE ratio of -4.61 and a beta of 1.69. The business's 50 day moving average is $20.35 and its two-hundred day moving average is $17.33. Neurogene has a one year low of $6.88 and a one year high of $74.49.

Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.10.

Hedge Funds Weigh In On Neurogene

A number of institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock worth $1,426,000 after buying an additional 42,880 shares in the last quarter. Schroder Investment Management Group bought a new position in Neurogene in the second quarter worth about $451,000. PNC Financial Services Group Inc. grew its holdings in Neurogene by 43.6% in the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock worth $61,000 after purchasing an additional 1,232 shares during the period. Jennison Associates LLC grew its holdings in Neurogene by 55.0% in the second quarter. Jennison Associates LLC now owns 167,563 shares of the company's stock worth $2,505,000 after purchasing an additional 59,479 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock worth $82,000 after purchasing an additional 1,059 shares during the period. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.